<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>JAK2 V617F mutation is mostly seen in BCR-ABLI negative myeloproliferative <z:hpo ids='HP_0002664'>neoplasms</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Among other myeloid <z:hpo ids='HP_0002664'>neoplasms</z:hpo>, it occurs with remarkably high frequency in <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with ring sideroblasts associated with marked <z:hpo ids='HP_0001894'>thrombocytosis</z:hpo>, a group of myeloid <z:hpo ids='HP_0002664'>neoplasms</z:hpo> with both dysplastic and proliferative features </plain></SENT>
<SENT sid="2" pm="."><plain>It has also been reported in occasional cases of <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> with isolated del(5q), often with a diagnosis of refractory cytopenia with multilineage <z:mpath ids='MPATH_589'>dysplasia</z:mpath> </plain></SENT>
<SENT sid="3" pm="."><plain>We performed a retrospective analysis of JAK2 V617F mutation in Chinese patients with myeloid <z:hpo ids='HP_0002664'>neoplasms</z:hpo> and isolated del(5q), and were able to demonstrate the frequent occurrence of JAK2 V617F mutation in <z:e sem="disease" ids="C0740302" disease_type="Disease or Syndrome" abbrv="">5q- syndrome</z:e> </plain></SENT>
</text></document>